Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Shanghai
Clinical trial register · China

Clinical Trials in Shanghai, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19377 matching records held by the registry are in this view. Synced 19 Nov 2026, 03:17 UTC
19377
Studies in scope
all four open statuses
11904
Recruiting now
open to new participants
2037
Lead sponsors
across recruiting studies
Top sites
Beijing 18 Shanghai 16 Guangzhou 12 Fuzhou 11 Changsha 10

Trials with a site in Shanghai

16 of 19377 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
NCT07707895Small Cell Lung Cancer, Large Cell Neuroendocrine Lung Carcinoma, Extrapulmonary Neuroendocrine Carcinoma of Small Cell Histology, Extrapulmonary Neuroendocrine Carcinoma of Large Cell Histology
Boehringer Ingelheim
Phase 1/2
60
Nanning, Shanghai
2026-11-03
Recruiting
Amgen
Phase 3
400
Beijing, Shanghai
2026-08-28
Recruiting
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
NCT07476287Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Transformed Small Cell Lung Cancer, Lung Neoplasms
Pfizer
Phase 2
40
Beijing, Fuzhou, Zhengzhou, Wuhan, Nanchang, Shanghai, Hangzhou
2026-07-02
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1
100
Shanghai
2026-04-21
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 3
420
Shanghai
2025-12-12
Active, closed
Amgen
Phase 3
350
Beijing, Quanzhou, Harbin, Jiamusi, Zhengzhou, Nanchang, Jinan, Shanghai
2025-08-18
Recruiting
Merck Sharp & Dohme LLC
Phase 1/2
327
Beijing, Fuzhou, Nanjing, Shanghai, Chengdu, Hangzhou
2025-02-27
Not yet open
A Multicenter, Open-label Phase IIa Clinical Study to Evaluate the Efficacy and Safety of B1962 Injection in the Treatment of Advanced Malignant Solid Tumors
NCT06724263Recurrent Platinum-resistant Epithelial Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Cervical Cancers, Small Cell Lung Cancer
DrugB1962
Tasly Biopharmaceuticals Co., Ltd.
Phase 2
120
Shanghai
2024-12
Recruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Phase 1/2
265
Shanghai
2024-09-02
Recruiting
Biokin (Shanghai) Biopharmaceutical Co., Ltd.
Phase 1
115
Shanghai
2024-08-02
Recruiting
Ruijin Hospital
Not applicable
104
Shanghai
2021-01-30
Active, closed
PF-07104091 as a Single Agent and in Combination Therapy
NCT04553133Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer
Pfizer
Phase 2
157
Shanghai, Tianjin
2020-09-16
Recruiting
Shanghai Pulmonary Hospital, Shanghai, China
Phase 2
40
Shanghai
2020-09-01
Recruiting
Clinical Safty and Efficacy Study of Infusion of iNKT Cells and CD8+T Cells in Patients With Advanced Solid Tumor
NCT03093688Non-small Cell Lung Cancer, Small Cell Lung Cancer, Pancreas Cancer, Hepatocellular Carcinoma
Shanghai Public Health Clinical Center
Phase 1/2
40
Shanghai
2017-03-01
Recruiting
Molecular Analysis and Treatment Options of SCLC
NCT05945745Small-cell Lung Cancer, Small Cell Lung Cancer, Combined Type, Small Cell Lung Carcinoma, Small Cell Lung Cancer Extensive Stage
Shanghai Chest Hospital
Observational
500
Shanghai
2016-01-01
Rows per page Showing 1–16 of 16
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 19 November 2026. https://priyalifescience.com/clinical-trials-china/city/shanghai

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,377 studies in total at the last sync on 19 Nov 2026, 03:17 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 16 of those studies with a site in Shanghai that also match the filters currently applied.

How many clinical trials are recruiting in Shanghai?

13 of the 16 studies on this page are recruiting new participants as of the 19 Nov 2026, 03:17 UTC sync. A further 1 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Shanghai), 16 studies
PhaseStudiesRecruitingShare
Phase 25331.3%
Phase 1/24425%
Phase 33218.8%
Phase 12212.5%
Not applicable116.3%
Observational116.3%

Most active sponsors

Lead sponsors with the most studies (Shanghai)
Lead sponsorStudiesRecruiting
Suzhou Zelgen Biopharmaceuticals Co.,Ltd33
Amgen21
Pfizer21
AbbVie11
Biokin (Shanghai) Biopharmaceutical Co., Ltd.11
Boehringer Ingelheim11
Merck Sharp & Dohme LLC11
Ruijin Hospital11
Shanghai Chest Hospital11
Shanghai Public Health Clinical Center11
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.